Advanced Flower Capital (AFCG) Q4 2024 earnings summary

Executive summary

• Achieved $135 million in new loan originations in 2024, surpassing the $100 million target, and focused exclusively on cannabis lending after spinning off the commercial real estate portfolio in July.

• Reported 2024 distributable earnings of $34.9 million ($1.68 per share) and GAAP net income of $16.8 million ($0.78 per share), with Q4 distributable earnings of $6.3 million ($0.29 per share) and a GAAP net loss of $1 million ($0.05 per share).

• Enhanced portfolio diversification and underwriting, emphasizing lending to proven cannabis operators and reducing construction lending exposure.

• Actively managed underperforming credits, receiving $119 million in paydowns from five such loans and redeploying capital into nine new loans.

• Maintained a robust origination pipeline, with $383 million in active opportunities as of March 1, 2025.

Financial highlights

• Book value per share declined from $15.64 at year-end 2023 to $9.02 at year-end 2024, impacted by spin-off distributions and CECL adjustments.

• Net interest income for Q4 was $7.6 million; for the year, $45.7 million.

• Q4 2024 interest income was $9.2 million; full year interest income reached $52.0 million.

• Declared a Q1 2025 dividend of $0.23 per share, reflecting a sustainable payout based on current performing assets.

• Weighted average portfolio yield to maturity was approximately 18% as of March 1, 2025.

Outlook and guidance

• Active deal pipeline exceeds $380 million as of March 1, 2025, with a focus on high-quality, limited-license states.

• Management expects to continue diversifying the portfolio and redeploying capital from underperforming assets into higher-quality credits.

• No new origination target set for 2025 yet; guidance to be provided next quarter due to recent portfolio developments.

• The company anticipates increased M&A activity and further expansion of the addressable market as more states transition to adult-use cannabis.

• Management expects the capital supply-demand imbalance in cannabis to persist, offering opportunities for risk-adjusted returns.